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Despite efforts to raise awareness and develop guidelines for care of individuals with dementia, reports of poor detection and
inadequate management persist.This has led to a call for more identification of people with dementia, that is, screening individuals
whomay ormay not complain of symptoms of dementia in both acute settings and primary care.The following should be considered
before recommending screening for dementia among individuals in the general population.Dementia Tests. Low screening reduces
positive predictive value of tests and screening tests will miss people who have dementia and identify people who do not have
dementia in substantial numbers. Clinical Issues. The clinical course of dementia has not yet been shown to be amenable to
intervention. Misdiagnosis and overdiagnosis can have significant long-term effects including stigmatization, loss of employment,
and autonomy. Economic Issues. Health systems do not have the capacity to respond to increased demand resulting from screening.
In conclusion, at present attention to life-course risk reduction and support in the community for frail and cognitively impaired
older adults is a better use of limited healthcare resources than introduction of unevaluated dementia screening programs.
1. Introduction
Dementia is a condition with multiple causes that affects
memory, other cognitive abilities, and behaviour that inter-
fere with a person’s ability to drive, deal with their finances,
manage their healthcare, and live independently [1]. Also,
dementia has a significant impact not only on individuals
but also on their careers, families, communities, and societies
[2].
Alzheimer’s disease and vascular dementia are the most
common forms of dementia and other causes are dementia
with Lewy bodies and a group of diseases that contribute to
frontotemporal dementia [2]. In 2015, dementia affected 47
million people worldwide, that is estimated to increase to 75
million in 2030 and 132 million by 2050 [3]. Recent reviews
estimate that globally nearly 9.9 million people develop
dementia each year [3].
Though age is by far the strongest known risk for the
onset of the common dementias, not all older adults develop
dementia. Also, younger adults develop dementia (defined as
the onset of symptoms before the age of 65 years) accounting
for less than 9% of cases [2].
Risk reduction and maintenance of cognitive abilities is
known to be associated with particular behaviours and envi-
ronments, similar to other long-term diseases [4]. Dementia
risk is lower for people who have been physically active,
avoided overweight, had balanced diets, did not smoke, and
hadmoderate use of alcohol as well as avoiding andmanaging
specific conditions such as high blood pressure, stroke, and
diabetes mellitus [4].
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Table 1: Six testing, clinical, and economic conditions for determining whether screening for dementia among “apparently” healthy
individuals does more good than harm.
Dementia tests
(i) How feasible is it to accurately identify individuals with high likelihood of dementia via screening tests?
(ii) What is the estimated prevalence of dementia in the population to be screened?
Clinical issues
(i) Is the clinical course of dementia amenable to intervention and if yes at what stage and is their adequate evidence?
(ii) What are the reasons and value of an individual knowing a diagnosis of dementia?
Economic issues
(i) Does the healthcare system have the capacity to respond to increased demand resulting from screening for dementia?
(ii) Will screening add value to individuals with dementia, the healthcare system, and society?
In our view, there is a profound disconnect between the
assertions of some researchers and journals and the wider
practitioner and other researcher clinician communities that
healthy populations be screened for dementia to identify
individuals with dementia early [5–8]. “Early” here includes
screening in situations where neither the individual nor
his/her caregiver have noticed any symptoms, or have judged,
or recognised them, as needing clinical assessment. “Healthy”
here refers to the WHO definition, “the extent to which an
individual or group is able to realize aspirations and satisfy
needs, and to change or cope with the environment. Health is
a resource for everyday life, not the objective of living; it is a
positive concept, emphasizing social and personal resources,
as well as physical capacities” [9].
While the motivation for screening is well intentioned,
four recent reports [10–13] by expert panels that systemati-
cally reviewed the dementia screening evidence recommend
not screening individuals who are not themselves, or their
families, seeking such attention (Recent Reviews on Demen-
tia Screening). We think that the following case example can
help illustrate different perspectives and assessment of the
balance of potential benefit and harm.
Recent Reviews on Dementia Screening. See [10–13].
2. Case Presentation (Hypothetical)
The local Alzheimer Association requested advice from the
local medical society to introduce an awareness raising cam-
paign to screen for dementia. Practitioners often see individ-
uals who once diagnosed have a clear view that their delay
in accessing support and advice from services have caused
harm and that this can be remedied by systematic screening.
They feel that early detection and remediation could lead
to improved quality of life for affected individuals and
their caregivers. The Alzheimer Association states that their
supports and other activities are available for any individuals
with identified problems. They believe that making the test
results known to caregivers and the Association will assist
individuals when identified early. Many jurisdictions have
begun such campaigns and are enthusiastic about them. Con-
cerned caregivers in your community are encouraging the
Alzheimer Association to follow suit. You are part of a
committee asked by themedical society to prepare an answer.
Your report will be due next week.
3. Use of Critical Appraisal to Assist in
Deciding Whether or Not to Screen
Public resources are involved in this decision. Funding used
for one activity is not then available for another. Deciding to
screen or not should therefore be based on explicit criteria. A
collection of previous experiences and the evolution of rules
of evidence about screening [14] were fused into the three
following areas: testing, clinical decisions, and economic con-
siderations. These criteria can be used to determine, on the
basis of current evidence, whether screening causes more
harm than good in individuals who have not sought medical
attention.The rest of this article will describe these and show
how to use them when appropriate for a given population
(Table 1).
4. Dementia Tests
4.1. How Feasible Is It to Accurately Identify Individuals
with High Likelihood of Dementia via Screening? Psychome-
tric properties differ according to populations and settings
(community, tertiary, secondary, and primary care). The
test quality for dementia is influenced by many factors that
include age, culture, occupation, education, environmental
context, and health variables (medications, delirium, and
depression).
A recent systematic review reported 22 short validated
cognitive tests [15], so practitioners have to consider which to
use and interpret the results, taking into account the setting
and the individual patient’s premorbid education, language
and literacy skills and any current motor, and hearing and
visual impairment. For example, two dementia screening
tests used by primary care practitioners for apparently healthy
individuals are the Mini Mental State Examination [16] and
the Montreal Cognitive Assessment [17]. However, as many
as 1 in 8 healthy individuals screened for dementia and
mild cognitive impairment are incorrectly classified using the
MMSE. As many as 1 in 4 are screened incorrectly using the
MoCA [12, 18, 19]. This level of “false positives” can cause
harm from an emotional health and practical stand point. In
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Table 2: The effect of prevalence on the predictive value of a screening test.
Prevalence
Low (6%)
screening∗
Moderate
(30%)
case-finding∗∗
High
(80%)
diagnosis∗∗∗
Test Definitive diagnosis of condition
Present Absent Total Present Absent Total Present Absent Total
Abnormal 48 94 142 240 70 310 640 20 660
Normal 12 846 858 80 630 690 160 180 340
Total 60 940 1000 300 700 1000 800 200 1000
Predictive value of an abnormal test
48
142
× 100 = 34% 240
310
× 100 = 77% 640
666
× 100 = 97%
Hypothetical sensitivity = 80%, specificity = 90%
∗All people on a family health roster. ∗∗All people in a memory disorder clinic. ∗∗∗All people in a locked unit in a long-term care facility.
some jurisdictions, a diagnosis for dementiamay cause denial
of health insurance and may affect an individual’s right to
drive (see also Section 6.2 below).
Tests for dementia are just the beginning of the process
required to arrive at a diagnosis of dementia. Features and
typical trajectories of dementia include an understanding
of the differences between expected changes and ones that
signal deficits related to disability. Test interpretation requires
acknowledging the wide variability in changes in cognitive
ability over time, in older adults. In addition, medication,
including polypharmacy, and comorbid conditions must be
taken into consideration. In usual older people the “normal
ranges” of cognitive tests have not been tested in whole pop-
ulations. Screening tests applied in clinics will not perform in
the sameway in different population settings (see Section 4.2.
below).
The diagnosis of dementia must rule out treatable condi-
tions that contribute to cognitive deficits and declines. These
include sleep apnea, hypothyroidism, depression, polyphar-
macy, delirium, and declines in vision and hearing. If a
primary care team screen targeted groups who, themselves
or their families/community, have not sought help for any
concerns and are aged 80 years and over the process will
identify many other conditions: high blood pressure (41%),
depression (32%), heart disease (27%), transient ischaemic
attack (18%), and diabetes (13%) [20].
4.2. What Is the Estimated Prevalence of Dementia in the Pop-
ulation to Be Screened? Positive predictive value (PPV) is the
probability that a positive test result is correct in those who
test positive. The prevalence of dementia in the population
being screened has a dramatic impact on the PPV of a test,
even if there is consistent sensitivity and specificity. As shown
in Figure 1(a) (Table 2), in a locked unit in a long-term care
home, where the prevalence of dementia is 80%, regardless of
the accuracy of the test, the PPV is 97%. In a Memory Clinic
where the prevalence of dementia is 30%, the PPVof the test is
77% (using the same testwith equal sensitivity and specificity)
(Figure 1(b)) (Table 2). Even in this setting 1/4 people will
receive the possibility that their positive screening is wrong.
Prevalence of dementia is ∼6% [21] in the general population
or in a primary care clinic and this results in the PPV of the
test dropping to 34% even with the sensitivity and specificity
being held steady (Figure 1(c)) (Table 2). This means that
between 6 and 7 people out of every 10 who tested positive
will not then be diagnosed as demented.
Primary and community care settings involve screening
thousands of individuals. Figure 1(c) demonstrates that 10%
of individuals screened in these settings will be mislabeled.
The number mislabeled would be 100,000 if a million indi-
viduals were screened in the general population or in a
primary care clinic. However, “. . . the magnitude of these
figures in even an opportunistic screening program result
in problems not only at the primary care level but also on
the specialist level to handle the volumes of people with a
suspected cognitive impairment” [22].
Between 1997 and 2011, incentives in the UK lead to a
dramatic increase in the number of referrals, but it led to no
increase in the prevalence of dementia [23]. However, in 2014,
the United Kingdom Department of Health introduced a m55
incentive for general practice physician offices to screen and
diagnose dementia [24]. Memory Disorder Clinics reported
having more individuals with functional memory problems
and an increase in personswith depression following this pol-
icy. Testing of low B12 and folate levels consistently occurred.
Mood testing only occurred in 26% of the population being
screened for dementia despite knowledge that depression is
a common and treatable risk factor for dementia [25]. In
2016, the monetary incentive for general practice physicians
in the United Kingdom to screen and diagnose dementia was
phased out.
An alternative argument to screening for dementia
among apparently healthy older adults has been put forward
to screen for general well-being [26]. Here the argument is
that the evidence shows that older adults with higher well-
being are able to adapt their psychological well-being to
numerous impairments and diseases [27, 28]. The resilience
and flexibility to adapt are the norm up to very old age,
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Number of people memory
test labelled as having
memory decit:
(hypothetical test sensitivity
= 80%, specicity = 90%)
% with dementia
(truth):
Care settings:
All 100
complete
memory
test
100 people
seen in a
locked unit
in a care
home
80%
labelled as “dementia”
Mislabelled Labelled correctly
(i) Do not have dementia but
continue to receive care in a
locked unit in a care home
(i) Continue to receive care in a
locked unit in a care home
66
2 64
See Table 2 for table showing calculations
(a) Impact of memory testing in a locked unit in a care home in mislabelling of dementia
All 100 
complete 
memory 
test
30%
24
labelled as “dementia”
Number of people memory
test labelled as having 
memory decit: (hypothetical 
test sensitivity = 80%, 
specicity = 90%)
% with dementia 
(truth):
7
Care settings:
100 people 
seen in a 
Memory 
Disorder 
Clinic
Mislabelled Labelled correctly
(i) Anxious people with
“dementia” label
(ii) Clinic initiates diagnostic
work-up
(i) Clinic initiates diagnostic
work-up
(ii) Proceed to “effective care
practice” interventions
31
See Table 2 for table showing calculations
(b) Impact of memory testing in memory disorder clinics in mislabelling of dementia
Number of people memory
test labelled as having
memory decit: (hypothetical
test sensitivity = 80%,
specicity = 90%)
% with dementia
(truth):
Care settings:
100 people 
seen in a 
family 
physician’s 
office
All 100 
complete 
memory 
test
6%
4
labelled as “dementia”
10 Mislabelled Labelled correctly
(i) Anxious people with 
“dementia” label
(ii) Risk of unnecessary treatment
(iii) Family physician initiates
diagnostic work-up
(i) Family physician initiates 
diagnostic work-up
(ii) Proceed to “effective care 
practice” interventions
14
See Table 2 for table showing calculations
(c) Impact of memory testing in family physician’s offices in mislabelling of dementia
Figure 1
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Figure 2: Screening: assumptions about the clinical course of a
health condition.
and only in the last period of life, severe disability, or frailty
does well-being decline [29]. Using well-being assessment
measures in primary care clinics could reveal those individ-
uals who have room for improvement in well-being and they
may be the best candidates for cognitive testing. However,
“. . .if an older person or his family has realized a stable and
well-adapted way of living, even in the case of cognitive
decline, added value of treating for cognitive decline is highly
questionable and is best delayed” [26]. In summary, current
testing methods are inaccurate, so that not only are people
misdiagnosed with dementia, but also true cases are missed.
5. Clinical Issues
5.1. Is the Clinical Course of Dementia Amenable to Interven-
tion and If Yes at What Stage and Is There Adequate Evidence?
Most common dementias are attributed to a combination
of Alzheimer’s type and vascular pathologies [30, 31]. The
average age of onset of dementia is in a person’s early 80s [21].
Mild stages of dementia are being identified increasingly in
clinical practice, with a drift toward predementia diagnosis at
younger ages.
Screening should occur after any condition’s biologic
onset but before usual diagnosis and treatment to improve
the course of consequences of having the condition. The
prerequisite assumption is that screening for dementia among
previously undiagnosed individuals leads to improvement in
quality of life vis-a`-vis unscreening individuals (Figure 2).
Although very important for decision-making about
interventions, the stages of dementia (mild, moderate, and
severe) lack clinical consensus and therefore the stage of
dementia is not routinely reported by clinicians. The pathol-
ogy accompanying dementia among older individuals is
complex [32–36]. New research on biomarkers may or may
not change this situation.
Screening of apparently healthy individuals is only jus-
tified if there is an effective treatment for specific condi-
tions identified. Screening of populations or groups before
symptoms develop is clearly not justified at present as there
is no drug that arrests clinically diagnosed dementia of the
Alzheimer’s type. Clinical trials of cholinesterase inhibitors
have not been shown to improve the symptoms of dementia
with individuals who have mild cognitive impairments [10].
In addition, the substantial number ofwithdrawals from trials
suggests intolerance to these drugs [37]. As many as 40%
of individuals assessed as ‘mild cognitive impairment no
dementia’may remain the same in the following five years and
many improve [38, 39].
5.2.What Are the Reasons andValue of an Individual Knowing
a Diagnosis of Dementia? Some argue that screening of
apparently healthy individuals is a process that is independent
of the evidence of effectiveness of screening but more a
“right to know” about the condition. The “right to know” a
diagnosis [40] assumes the existence of a precise definition
of the condition. An understanding of the condition and
the underlying reasons in its clinical course and the clinical
course for the person, their age, and gender is also assumed.
The assumption continues with the impact of contextual
factors such as comorbidity, ethnicity, and education as
well as, in the case of dementia, relationship to end of
life. Prognostication is one aspect of a diagnosis, but even
superficial consideration of the current evidence highlights
the lack of a sufficient evidence base to inform such a
justification for a diagnosis through screening of apparently
healthy individuals [41]. More research is warranted before
any further calls for dementia screening of populations.
Prognosis with the dementias and predementia states is
already beset with uncertainty, even within a usual clinical
setting. Rarely is an individual provided with the scale and
range of uncertainty. Where prognosis is being imposed on
a previously undiagnosed individual through opportunistic
application of a screening test, it would seem important
that they are informed of the degree of uncertainty about
prognosis of testing positive. This parallels with breast can-
cer screening where public awareness of overdiagnosis and
overtreatment is growing [42, 43].
Screening leads to some misdiagnosis and overdiagnosis
for individuals including the harmful effects of diagnosis,
implications of taking diagnostic processes further, and
overtreatment. The consequences of dementia testing could
include being inaccurately labelled, stigmatization, prema-
ture curtailment of employment, and loss of support for day-
to-day functions, such as driving, remaining independent,
and making financial and healthcare decisions [44, 45].
6. Economic Issues
6.1. Does the Healthcare System Have the Capacity to Respond
to Increased Demand Resulting from Screening for Demen-
tia? Healthcare system challenges required to respond to
increased prevalence are likely to be substantial. For example,
primary care costs and specialist costs of diagnosing demen-
tia far exceed costs of diagnosing other common chronic
conditions for which diagnostic markers are available (e.g.,
hypertension). This is a small fraction of the lifetime costs of
care incurred by an individual with dementia [46].
Dramatic increases in memory clinic referrals follow-
ing increased screening of “apparently healthy” individuals
creates challenges for health and social services [10–13].
Unimpaired and worried individuals may be kept under
follow-up which uses up staff resources. This overburdening
of existing systems violates one of the principles of screening.
Opportunity costs can include fewer resources for those indi-
viduals diagnosed with dementia because of underresourced
and poorly coordinated health and social care that involves
multiple agencies and practitioners [47].
6.2. Will Screening Add Value to Individuals with Dementia,
the Healthcare System, and Society? Many members of the
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public believe that a treatment exists to reduce the existing
symptoms and effectively slow its progression. A significant
proportion believe that a reliable medical test to diagnose
dementia is currently available [48]. The reality is that
diagnosis is not always straightforward and there is no drug to
stopmost causes of dementia [49].There is a degree of uncer-
tainty that should be shared and understood that the process
of diagnosis has a number of uncertainties. This uncertainty
is increased because of the connection between cognitive
ability, neurobiology, ageing, end of life, and clinical course
for an individual. Informed consent is difficult to achievewith
this kind of uncertainty.
Recent studies of populations are revealing new concerns
about the value of screening to identify early dementia.
If referred to a specialist, an individual is twice as likely
to be institutionalized [50]. After the first year for people
newly diagnosedwith dementia, 65%will be transferred from
institution to institution, usually acute care hospitals, at least
once and 17% will have three or more healthcare practitioner
transitions [51]. These transitions can increase the risk of
medication errors, hospital readmissions, and deaths. When
receiving antipsychotic or benzodiazepine medications or
living in a rural area, the transitions increase. Older adults
receiving newly started cholinesterase inhibitor drug ther-
apy have more physicians providing care and have higher
anticholinergic drug burden scores [52]. These studies raise
questions about the importance of the psychosocial environ-
ment surrounding the person with dementia. This includes
domains of social networks (number of caregivers involved
in care decisions) or personality traits (self-care behaviour,
being unaware of cognitive inability) that may influence both
care referral and the clinical evolution. Overdiagnosis of
dementia is harmful and can interfere with a good quality of
life because of the altered self-perception and perception of
others aswell as stigmatization, early institutionalization, side
effects ofmedications, and premature shutdownof regular life
activities [42–45].
7. Case Conclusion
The medical society group that was advising the local
Alzheimer Association about the proposed community wide
awareness campaign on dementia screening examined the
evidence about the links of “apparently healthy” individuals.
It concluded that there were few interventions of rigorously
demonstrated efficacy for the symptoms of dementia that
would be detected among apparently healthy individuals, and
there was no acceptable evidence that the early detection of
most of the symptoms of dementia altered their prognoses.
The required studies simply had not been done indicating the
need for more research on the six questions outlined in this
report.
The committee shared the caregivers and the Alzheimer
Association concerns that a substantial burden of morbidity
affecting individuals, their caregivers, and the whole commu-
nity resulted from dementia.
The measurement properties of the available and feasible
screening tests were largely unknown in primary care set-
tings.
Moreover, it was judged that the oldest, old individuals
who were at the greatest risk for dementia, would be most
likely the group that might benefit from dementia screening.
The committee questioned whether dementia screening of
apparently healthy individuals was the best use of existing
Alzheimer Association and other specialized services.
The committee’s final recommendation was that the
resources available for the community-wide awareness cam-
paign on dementia screening should be used for research to
generate evidence on dementia screening in the community.
Additional Points
Considerable investment has been made by many societies
to raise awareness of dementia, including exhortations for
screening by some. Four recent reports by expert panels
that systematically reviewed the evidence about screening
for dementia and recommend not screening individuals who
are not themselves, or their families, seeking such attention.
Current evidence on testing, clinical decisions, and eco-
nomic considerations can be evaluated to estimate whether
screening could cause more harm than good in individuals
who have not presented for medical attention and may have
no symptoms. Considerable resources are currently being
used for dementia screening without an evidence base and
should be redirected and restructured to generate evidence on
dementia screening in the community and selected settings.
Disclosure
Views or opinions presented in this manuscript are solely
those of the authors and do not necessarily represent those
of their organizations. This manuscript was based on presen-
tations by Drs. Brayne and Chambers at the session entitled
“Does Dementia Screening Lead to Over-Diagnosis or an
Opportunity for Early Intervention?” during the Alzheimer
Association International Conference, held in Copenhagen,
in July, 2014.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
All three authors made substantial contributions to the
conception, design, acquisition, analysis, or interpretation
of data for the work. All three authors drafted the work
or revised it critically for important intellectual content. All
three authors have given their final approval of this version to
be published. All three authors agree to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved.
References
[1] IOM (Institute of Medicine), Cogntive Aging: Progress in Under-
standing and Opportunities for Action, The National Academies
Press, Washington, DC, USA, 2015.
Advances in Preventive Medicine 7
[2] Alzheimer’s Association, “2016 Alzheimer’s disease facts and
figures,” Alzheimer’s and Dementia, vol. 12, no. 4, pp. 459–509,
2016.
[3] Alzheimer’s Disease International, Dementia Statistics, 2017,
http://www.alz.co.uk/research/statistics.
[4] Alzheimer’s Disease International, World Alzheimer Report
2014: Dementia and Risk Reduction, 2017, http://www.alz.co.uk/
research/world-report-2014.
[5] J. C. Morris, J. Weng, and C. Xiong, “Subjective Cognitive
Decline Versus Informant Report,” in Proceedings of the Alz-
heimer Association International Conference 2014 Screening for
Alzheimer’s Disease in Cognitively Normal Older Adults, vol.
10, https://www.deepdyve.com/lp/elsevier/screening-for-alz-
heimer-s-disease-inhttps://www.deepdyve.com/lp/elsevier/screen-
ing-for-alzheimer-s-disease-in-cognitively-normal-older-adults-
r1IkxHjBA0cognitively-normal-older-adults-r1IkxHjBA0.
[6] B. Dubois, S. Epelbaum, A. Michon et al., “Screening for AD:
Why and How?” in Proceedings of the Alzheimer Association
International Conference 2014, 2016, http://www.alzheimers-
anddementia.com/article/S1552http://www.alzheimersanddemen-
tia.com/article/S1552-5260(14)00370-7/fulltext%20Accessed%
20February%2020165260(14)00370-7/fulltext.
[7] P. J. Bayley, J. Y. Kong, M. Mendiondo et al., “Findings from
the national memory screening day program,” Journal of the
American Geriatrics Society, vol. 63, no. 2, pp. 309–314, 2015.
[8] J. E. Morley, J. C. Morris, M. Berg-Weger et al., “Brain Health:
The Importance of Recognizing Cognitive Impairment: An
IAGG Consensus Conference,” Journal of the AmericanMedical
Directors Association, vol. 16, no. 9, pp. 731–739, 2015.
[9] World Health Organization, Regional Office for Europe. Health
promotion: A Discussion Document on the Concept and Prin-
ciples : Summary Report of the Working Group on Concept
and Principles of Health Promotion, WHO Regional Office for
Europe, Copenhagen, Denmark, 1984.
[10] JS. Lin et al., “Screening for cognitive impairment in older
adults: an evidence update for the united states preventive
services task force. evidence synthesis,” AHRQ Publication No.
14-05198-EF-1, 2013.
[11] Gerontology Society of America Workgroup on Cognitive
Impairment Detection and Earlier Diagnosis. Report and Recom-
mendations. The Gerontology Society of America, Washington,
DC,USA, 2015, https://www.geron.org/images/gsa/documents/
gsaciworkgroup2015report.pdf.
[12] Canadian Task Force on Preventive Health Care, K. Pottie,
R. Rahal et al., “Recommendations on screening for cognitive
impairment in older adults,” CMAJ, vol. 188, no. 1, pp. 37–46,
2015.
[13] “United Kingdom National Screening Committee, The UK
NSC recommendation on Screening for Dementia, London,
Public Health England, 2015,” https://legacyscreening.phe.org
.uk/dementia.
[14] J. M. G. Wilson and G. Jungner, Principles and practice of
screening for disease, WHO, Geneva, Switzerland, 1968, Avail-
able from http://apps.who.int/iris/bitstream/10665/37650/17/
WHO PHP 34.pdf.
[15] L. Velayudhan, S.-H. Ryu,M. Raczek et al., “Review of brief cog-
nitive tests for patients with suspected dementia,” International
Psychogeriatrics, vol. 26, no. 8, pp. 1247–1262, 2014.
[16] M. F. Folstein, S. E. Folstein, and P. R. McHugh, ““Mini-mental
state”. A practical method for grading the cognitive state of
patients for the clinician,” Journal of Psychiatric Research, vol.
12, no. 3, Article ID 1202204, pp. 189–198, 1975.
[17] Frequently Asked Questions, Montreal Cognitive Assessment,
Montre´al, Canada, 2015, http://www.mocatest.org/faq/.
[18] D. I. Kaufer, C. S.Williams,A. J. Braaten,K.Gill, S. Zimmerman,
and P. D. Sloane, “Cognitive Screening for Dementia and Mild
Cognitive Impairment in Assisted Living: Comparison of 3
Tests,” Journal of the American Medical Directors Association,
vol. 9, no. 8, pp. 586–593, 2008.
[19] L. Flicker, D. Logiudice, J. B. Carlin, and D. Ames, “The
predictive value of dementia screening instruments in clinical
populations,” International Journal of Geriatric Psychiatry, vol.
12, no. 2, pp. 203–209, 1997.
[20] All Party Parliamentary Group on Dementia, Dementia Rarely
Travels Alone: Living with Dementia and Other Conditions,
/APPG on Dementia 2016 Report(2).pdf, London, UK, 2016.
[21] Alzheimer Society of Canada, “Prevalence and Monetary Costs
of Dementia in Canada,” Alzheimer Society of Canada, Toronto,
Canada, 2016.
[22] A. Wimo and B. Winblad, “Brain Health: A Primary Health
Care Viewpoint,” Journal of the American Medical Directors
Association, vol. 16, no. 9, pp. 720-721, 2015.
[23] S. Iliffe and J. Wilcock, “The UK experience of promoting
dementia recognition and management in primary care,” Zeits-
chrift fu¨r Gerontologie und Geriatrie, vol. 50, pp. 63–67, 2017.
[24] S. Bell, K. Harkness, J. M. Dickson, and D. Blackburn, “A diag-
nosis for m55: What is the cost of government initiatives in
dementia case finding,” Age and Ageing, vol. 44, no. 2, Article
ID afu205, pp. 344-345, 2015.
[25] D. Gracia, “Institute of Medicine (IOM). The Learning Health-
care System: Workshop Summary. Washington, DC: The
National Academies Press, 2007,” EIDON nº39.
[26] M. G. M. Olde Rikkert, J. A. H. R. Claassen, and R. T. C. M.
Koopmans, “Do Not Harm Older Persons in Primary Care by
Case Finding of Cognitive Decline, Instead Assess Cognition
Only Following Loss of Well-being,” Journal of the American
Medical Directors Association, vol. 17, no. 5, pp. 456-457, 2016.
[27] D. Jopp, C. Rott, and F. Oswald, “Valuation of life in old and
very old age: The role of sociodemographic, social, and health
resources for positive adaptation,” Gerontologist, vol. 48, no. 5,
pp. 646–658, 2008.
[28] A. Steptoe, A. Deaton, and A. A. Stone, “Subjective wellbeing,
health, and ageing,”The Lancet, vol. 385, no. 9968, pp. 640–648,
2015.
[29] D. Jopp and C. Rott, “Adaptation in very old age: Exploring the
role of resources, beliefs, and attitudes for centenarians’ hap-
piness,” Psychology and Aging, vol. 21, no. 2, pp. 266–280, 2006.
[30] H. Agu¨ero-Torres, M. Kivipelto, and E. Von Strauss, “Rethink-
ing the dementia diagnoses in a population-based study: What
is Alzheimer’s disease and what is vascular dementia? A study
from the Kungsholmen project,”Dementia and Geriatric Cogni-
tive Disorders, vol. 22, no. 3, pp. 244–249, 2006.
[31] J. B. Toledo, S. E. Arnold, K. Raible et al., “Contribution of cere-
brovascular disease in autopsy confirmed neurodegenerative
disease cases in the National Alzheimer’s Coordinating Centre,”
Brain, vol. 136, no. 9, pp. 2697–2706, 2013.
[32] G. M. Savva, S. B.Wharton, P. G. Ince et al., “Age, Neuropathol-
ogy, and Dementia,”The New England Journal of Medicine, vol.
360, pp. 2302–2309, 2009.
[33] Neuropathology Group of the Medical Research Council Cog-
nitive Function and Ageing Study (MRC CFAS), “Pathological
correlates of late-onset dementia in a multicentre, community-
based population in England and Wales,” The Lancet, vol. 357,
no. 9251, pp. 169–175, 2001.
8 Advances in Preventive Medicine
[34] D. S. Knopman, J. E. Parisi, A. Salviati et al., “Neuropathology
of Cognitively Normal Elderly,” Journal of Neuropathology &
Experimental Neurology, vol. 62, pp. 1087–1095, 2003.
[35] J. A. Sonnen, E. B. Larson, P. K. Crane et al., “Pathological cor-
relates of dementia in a longitudinal, population-based sample
of aging,” Annals of Neurology, vol. 62, no. 4, pp. 406–413, 2007.
[36] D. G. Blazer, K. Yaffe, and C. T. Liverman, Eds., IOM (Institute
of Medicine), Cognitive Aging: Progress in Understanding
and Opportunties for Action, The National Academies Press,
Washington DC, 2015.
[37] D. Fitzpatrick-Lewis, R. Warren, M. U. Ali, D. Sherifali, and P.
Raina, “Treatment for mild cognitive impairment: a systematic
review andmeta—analysis,”CMAJOpen, vol. 3, no. 4, pp. E419–
E427, 2015.
[38] A. J. Mitchell and M. Shiri-Feshki, “Rate of progression of mild
cognitive impairment to dementia—meta-analysis of 41 robust
inception cohort studies,” Acta Psychiatrica Scandinavica, vol.
119, no. 4, pp. 252–265, 2009.
[39] J. T. Tschanz, K. A. Welsh-Bohmer, C. G. Lyketsos et al., “Con-
version to dementia from mild cognitive disorder: The Cache
County Study,” Neurology, vol. 67, no. 2, pp. 229–234, 2006.
[40] Alzheimer Society UK, Right to Know campaign—diagnosis and
support, 2015, http://www.alzheimers.org.uk/.
[41] A. J. Mitchell and S. Malladi, “Screening and case finding tools
for the detection of dementia. Part I: Evidence-based meta-
analysis of multidomain tests,” American Journal of Geriatric
Psychiatry, vol. 18, no. 9, pp. 759–782, 2010.
[42] H. G. Welsh and S. Schwartz LM Woloshin, Overdiagnosed:
Making People Sick in the Pursuit of Health, Beacon Press,
Boston, MA, USA, 2011.
[43] S. Brownlee,Overtreated:Why TooMuchMedicine is Making Us
Sick, Bloomsbury, New York, NY, USA, 2008.
[44] R. Moynihan, J. Doust, and D. Henry, “Preventing overdiag-
nosis: how to stop harming the healthy,” The British Medical
Journal, vol. 344, no. 7859, Article ID e3502, 2012.
[45] “Harding Centre for Health Literacy, General Health Check.
Max Planck Institute for Human Development,” Berlin,
Germany, 2016, https://www.harding-center.mpg.de/en/health-
information/fact-boxes/general-health-check.
[46] B. Winblad, P. Amouyel, S. Andrieu, and C. Ballard, “Defeating
Alzheimers disease and other dementias: a priority for Euro-
pean science and society,” Lancet Neurology, vol. 15, pp. 455–
532, 2016, Accessed March 2016, http://www.thelancet.com./
neurology.
[47] L. Lemieux-Charles, L. W. Chambers, R. Cockerill et al., “Eval-
uating the effectiveness of community-based dementia care
networks: the dementia care networks’ study,”TheGerontologist,
vol. 45, no. 4, pp. 456–464, 2005.
[48] Alzheimer’s Disease Europe, Public beliefs on existing treatments
and tests, 2011, Accessed February 2015, http://www.alzheimer-
europe.org/Research/Value-of-Knowing/Public-beliefs-on-exist-
ing-treatments-and-tests.
[49] J. Cummings, T. Morstorf, and G. Lee, “Alzheimer’s drug-
development pipeline: 2016,” Alzheimer’s & Dementia: Transla-
tional Research and Clinical Interventions, vol. 2, no. 4, pp. 222–
232, 2016.
[50] C. Pimouguet, M. Le-Goff, D. Rizzuto et al., “Effect of early
referral to specialist in dementia on institutionalization and
functional decline: findings from a population-based study,”
Journal of Alzheimer’s Disease, vol. 49, pp. 819–828, 2016.
[51] S. N. Sivananthan and K. M. McGrail, “Diagnosis and Dis-
ruption: Population-Level Analysis Identifying Points of Care
at Which Transitions Are Highest for People with Dementia
and Factors That Contribute to Them,” Journal of the American
Geriatrics Society, vol. 64, no. 3, pp. 569–577, 2016.
[52] C. E. Reppas-Rindlisbacher, H. D. Fischer, K. Fung et al., “Anti-
cholinergic Drug Burden in Persons with Dementia Taking
a Cholinesterase Inhibitor: The Effect of Multiple Physicians,”
Journal of theAmericanGeriatrics Society, vol. 64, no. 3, pp. 492–
500, 2016.
